MicroRNAs in the bile of patients with biliary strictures after liver transplantation

Tim O. Lankisch, Torsten Voigtländer, Michael P. Manns, Angelika Holzmann, Seema Dangwal, Thomas Thum – 20 March 2014 – Biliary complications after liver transplantation remain a major cause of morbidity and reduced graft survival. Ischemic‐type biliary lesions (ITBLs) are common and difficult to treat. The pathophysiology of ITBLs remains unclear, and diagnostic markers are still missing. The analysis of microRNA (miRNA) profiles is an evolving field in hepatology. Our aim was to identify specific miRNA patterns in the bile of patients with ITBLs after liver transplantation.

Integrated metabolic spatial‐temporal model for the prediction of ammonia detoxification during liver damage and regeneration

Freimut Schliess, Stefan Hoehme, Sebastian G. Henkel, Ahmed Ghallab, Dominik Driesch, Jan Böttger, Reinhard Guthke, Michael Pfaff, Jan G. Hengstler, Rolf Gebhardt, Dieter Häussinger, Dirk Drasdo, Sebastian Zellmer – 19 March 2014 – The impairment of hepatic metabolism due to liver injury has high systemic relevance. However, it is difficult to calculate the impairment of metabolic capacity from a specific pattern of liver damage with conventional techniques. We established an integrated metabolic spatial‐temporal model (IM) using hepatic ammonia detoxification as a paradigm.

Cost‐effectiveness analysis of liver resection versus transplantation for early hepatocellular carcinoma within the Milan criteria

Kheng Choon Lim, Vivian W. Wang, Fahad J. Siddiqui, Luming Shi, Edwin S.Y. Chan, Hong Choon Oh, Say Beng Tan, Pierce K.H. Chow – 18 March 2014 – Both liver resection (LR) and cadaveric liver transplantation (CLT) are potentially curative treatments for patients with hepatocellular carcinoma (HCC) within the Milan criteria and with adequate liver function. Adopting either as a first‐line therapy carries major cost and resource implications.

Diagnosis of sinusoidal obstruction syndrome by positron emission tomography/computed tomography: Report of two cases treated by defibrotide

Mathieu Gauthé, Laurence Bozec, Pierre Bedossa – 17 March 2014 – Sinusoidal obstruction syndrome (SOS) is a potentially fatal liver injury that mainly occurs after myeloablative chemotherapy. We report two cases of SOS investigated by 18F‐fluorodeoxyglucose positron emission tomography/computed tomography and treated with defibrotide. (Hepatology 2014;60:1789–1791)

Diagnosis of sinusoidal obstruction syndrome by positron emission tomography/computed tomography: Report of two cases treated by defibrotide

Mathieu Gauthé, Laurence Bozec, Pierre Bedossa – 17 March 2014 – Sinusoidal obstruction syndrome (SOS) is a potentially fatal liver injury that mainly occurs after myeloablative chemotherapy. We report two cases of SOS investigated by 18F‐fluorodeoxyglucose positron emission tomography/computed tomography and treated with defibrotide. (Hepatology 2014;60:1789–1791)

Recurrence of primary sclerosing cholangitis in pediatric liver transplant recipients

Veena L. Venkat, Sarangarajan Ranganathan, George V. Mazariegos, Qing Sun, Rakesh Sindhi – 17 March 2014 – There is little detailed clinical information on recurrent primary sclerosing cholangitis (rPSC) after liver transplantation in children. Our purpose was to describe the characteristics of children who had experienced rPSC after liver transplantation so that we could identify potential risk factors for recurrence.

Intraoperative hemodialysis during liver transplantation: A decade of experience

Mitra K. Nadim, Wanwarat Annanthapanyasut, Lea Matsuoka, Kari Appachu, Mark Boyajian, Lingyun Ji, Ashraf Sedra, Yuri S. Genyk – 17 March 2014 – Liver transplantation (LT) for patients with renal dysfunction is frequently complicated by major fluid shifts, acidosis, and electrolyte and coagulation abnormalities. Continuous renal replacement therapy (CRRT) has been previously shown to ameliorate these problems. We describe the safety and clinical outcomes of intraoperative hemodialysis (IOHD) during LT for a group of patients with high Model for End‐Stage Liver Disease (MELD) scores.

Subscribe to